fiber optic holder hcs004 Search Results


human methylcellulose complete media without epo  (R&D Systems)
93
R&D Systems human methylcellulose complete media without epo
Figure 4. Combination toxicity study shows gemcitabine bone marrow toxicity is not potentiated significantly with GNE-900. Bliss plot of synergistic antiproliferative effects of GNE-900 in combination with gemcitabine in (A) HT-29 (p53-mutant) cells (3-day viability assay), or (B) human bone marrow cells (10-day <t>methylcellulose</t> culture viability assay). To evaluate the myelosuppressive effects in animals, Sprague-Dawley rats (n ¼ 3) were treated with 30 mg/kg gemcitabine, 25 mg/kg GNE-900, or 30 mg/kg gemcitabine followed 24 hours later by 25 mg/kg GNE-900. C, histopathology was assessed in hematoxylin and eosin–stained sections of femur bone marrow harvested on day 7. Scale bar, 100 mm.
Human Methylcellulose Complete Media Without Epo, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fiber+optic+holder+hcs004/Human+Methylcellulose+Complete+Media+Without+Epo/10__1158_slash_1535___7163__mct___12___1218-57-20-26
Average 93 stars, based on 1 article reviews
human methylcellulose complete media without epo - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


Figure 4. Combination toxicity study shows gemcitabine bone marrow toxicity is not potentiated significantly with GNE-900. Bliss plot of synergistic antiproliferative effects of GNE-900 in combination with gemcitabine in (A) HT-29 (p53-mutant) cells (3-day viability assay), or (B) human bone marrow cells (10-day methylcellulose culture viability assay). To evaluate the myelosuppressive effects in animals, Sprague-Dawley rats (n ¼ 3) were treated with 30 mg/kg gemcitabine, 25 mg/kg GNE-900, or 30 mg/kg gemcitabine followed 24 hours later by 25 mg/kg GNE-900. C, histopathology was assessed in hematoxylin and eosin–stained sections of femur bone marrow harvested on day 7. Scale bar, 100 mm.

Journal: Molecular Cancer Therapeutics

Article Title: Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

doi: 10.1158/1535-7163.mct-12-1218

Figure Lengend Snippet: Figure 4. Combination toxicity study shows gemcitabine bone marrow toxicity is not potentiated significantly with GNE-900. Bliss plot of synergistic antiproliferative effects of GNE-900 in combination with gemcitabine in (A) HT-29 (p53-mutant) cells (3-day viability assay), or (B) human bone marrow cells (10-day methylcellulose culture viability assay). To evaluate the myelosuppressive effects in animals, Sprague-Dawley rats (n ¼ 3) were treated with 30 mg/kg gemcitabine, 25 mg/kg GNE-900, or 30 mg/kg gemcitabine followed 24 hours later by 25 mg/kg GNE-900. C, histopathology was assessed in hematoxylin and eosin–stained sections of femur bone marrow harvested on day 7. Scale bar, 100 mm.

Article Snippet: For the bonemarrowassay, freshhumanbonemarrow– derived cells were obtained from AllCells and plated at a density of 1 million cells/mL in Human Methylcellulose Complete Media without Epo (R&D Systems; #HCS004).

Techniques: Mutagenesis, Viability Assay, Histopathology, Staining